guest ::
| Home > Publications Database > Dataset: Plasma proteomics of mice treated with BACE inhibitors > print |
| Home > Publications Database > Dataset: Plasma proteomics of mice treated with BACE inhibitors > print |
| 001 | 279490 | ||
| 005 | 20250709100939.0 | ||
| 037 | _ | _ | |a DZNE-2025-00817 |
| 100 | 1 | _ | |a Müller, Stephan A |0 P:(DE-2719)2810938 |b 0 |u dzne |
| 245 | _ | _ | |a Dataset: Plasma proteomics of mice treated with BACE inhibitors |
| 260 | _ | _ | |c 2024 |b PRoteomics IDEntifications Database |
| 336 | 7 | _ | |a MISC |2 BibTeX |
| 336 | 7 | _ | |a Dataset |b dataset |m dataset |0 PUB:(DE-HGF)32 |s 1752047288_8074 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a Chart or Table |0 26 |2 EndNote |
| 336 | 7 | _ | |a Dataset |2 DataCite |
| 336 | 7 | _ | |a DATA_SET |2 ORCID |
| 336 | 7 | _ | |a ResearchData |2 DINI |
| 520 | _ | _ | |a The Beta-secretase BACE1 is a central drug target for Alzheimer’s disease. Clinically tested, BACE1-directed inhibitors also block the homologous protease BACE2. Yet, little is known about physiological BACE2 substrates and functions in vivo. To discover potential BAC2 substrates in plasma, mice were treated with a non-specific BACE inhibitor (Cpd89) and a BACE1 preferring inhibitor (LY2811376). Plasma proteomics using DIA showed a reduced abundance of soluble FLT4 (sVEGFR3) for the non-specific inhbtor but not for the BACE1 preferring inhibitor. Conclusively, sVEGFR3 is a potential marker for BACE2 inhibition in plasma. |
| 536 | _ | _ | |a 352 - Disease Mechanisms (POF4-352) |0 G:(DE-HGF)POF4-352 |c POF4-352 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to DataCite |
| 700 | 1 | _ | |a Lichtenthaler, Stefan |0 P:(DE-2719)2181459 |b 1 |u dzne |
| 787 | 0 | _ | |a Schmidt, Andree et.al. |d Ann Arbor, Mich. : ASCJ, 2024 |i RelatedTo |0 DZNE-2024-01041 |r |t The Alzheimer's disease-linked protease BACE2 cleaves VEGFR3 and modulates its signaling. |
| 856 | 4 | _ | |u https://wwwdev.ebi.ac.uk/pride/archive/projects/PXD042669 |
| 909 | C | O | |o oai:pub.dzne.de:279490 |p VDB |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 0 |6 P:(DE-2719)2810938 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 1 |6 P:(DE-2719)2181459 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-352 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Disease Mechanisms |x 0 |
| 920 | 1 | _ | |0 I:(DE-2719)1110006 |k AG Lichtenthaler |l Neuroproteomics |x 0 |
| 980 | _ | _ | |a dataset |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-2719)1110006 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|